


**Claim Amendments**

This listing of claims will replace all prior versions, and listings, of claims in the application.

Claims 1-10. (Canceled)

Claim 11. (Currently Amended) A piperazine benzothiazole compound having formula I



as well as its tautomers, its geometrical isomers, its optically active forms as an enantiomer, a diastereomer and as a racemate, as well as pharmaceutically acceptable salts thereof, wherein

R is selected from the group comprising or consisting of hydrogen, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>1</sub>-C<sub>6</sub>-alkyl aryl, heteroaryl, C<sub>1</sub>-C<sub>6</sub>-alkyl heteroaryl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl aryl, C<sub>2</sub>-C<sub>6</sub>-alkenyl heteroaryl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl aryl, C<sub>2</sub>-C<sub>6</sub>-alkynyl heteroaryl, C<sub>3</sub>-C<sub>8</sub>-cycloalkyl, heterocycloalkyl, C<sub>1</sub>-C<sub>6</sub>-alkyl cycloalkyl, C<sub>1</sub>-C<sub>6</sub>-alkyl heterocycloalkyl, C<sub>1</sub>-C<sub>6</sub>-alkyl carboxy, acyl, C<sub>1</sub>-C<sub>6</sub>-alkyl acyl, acyloxy, C<sub>1</sub>-C<sub>6</sub>-alkyl acyloxy, C<sub>1</sub>-C<sub>6</sub>-alkyl alkoxy, alkoxycarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl alkoxycarbonyl, aminocarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl aminocarbonyl, acylamino, C<sub>1</sub>-C<sub>6</sub>-alkyl acylamino, ureido, C<sub>1</sub>-C<sub>6</sub>-alkyl ureido, amino, C<sub>1</sub>-C<sub>6</sub>-alkyl amino, sulfonyloxy, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonyloxy, sulfonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonyl, sulfinyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfinyl, sulfanyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfanyl, sulfonylamino, and C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonylamino;

$R^1$  is selected from the group comprising or consisting of H, halogen, cyano, nitro, amino,  $C_1$ - $C_6$ -alkyl,  $C_2$ - $C_6$ -alkenyl,  $C_2$ - $C_6$ -alkynyl,  $C_1$ - $C_6$ -alkyl-aryl, aryl or heteroaryl,  $C_1$ - $C_6$ -alkyl-heteroaryl,  $-C(O)-OR^2$ ,  $-C(O)-R^2$ ,  $-C(O)-NR^2R^{2'}$ , and  $-(SO_2)R^2$ , with

$R^2$  and  $R^{2'}$  being independently selected from the group ~~comprising or~~ consisting of hydrogen,  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl, aryl, heteroaryl,  $C_1$ - $C_6$ -alkyl aryl,  $C_1$ - $C_6$ -alkyl heteroaryl and combinations mixtures thereof; and

n is an integer from 0 to 3.

Claim 12. (Previously Presented) The piperazine benzothiazole compound according to claim 11, wherein  $R^1$  is hydrogen.

Claim 13. (Previously Presented ) The piperazine benzothiazole compound according to claim 11, wherein R is selected from the group consisting of hydrogen,  $C_1$ - $C_3$  alkyl, aminocarbonyl,  $C_1$ - $C_6$ -alkyl alkoxycarbonyl,  $C_1$ - $C_6$ -alkyl alkoxy,  $C_1$ - $C_6$ -alkyl acyloxy, alkoxycarbonyl, and  $C_1$ - $C_6$ -alkyl aminocarbonyl.

Claim 14. (Previously Presented) The piperazine benzothiazole compound according to claim 13, wherein R is H, or  $C_1$ - $C_3$  alkyl, in particular a methyl or an ethyl moiety, or  $C_1$ - $C_6$ -alkyl alkoxy.

Claim 15. (Previously Presented) The piperazine benzothiazole compound according to claim 11, wherein n is 1.

Claim 16. (Previously Presented) The piperazine benzothiazole compound according to claim 11 selected from the group consisting of:

1,3-benzothiazol-2-yl[2-({4-[(4-methylpiperazin-1-yl)methyl]benzyl}oxy)pyrimidin-4-yl]acetonitrile,

1,3-benzothiazol-2-yl[2-({4-[(4-benzyl-piperazin-1-yl)methyl]-benzyl}oxy)pyrimidin-4-yl]acetonitrile,

1,3-benzothiazol-2-yl(2-{[4-(piperazin-1-ylmethyl)benzyl]oxy}pyrimidin-4-yl)acetonitrile,

1,3-benzothiazol-2-yl[2-({4-[(4-formylpiperazin-1-yl)methyl]benzyl}oxy)pyrimidin-4-yl]acetonitrile,

[2-({4-[(4-acetyl)piperazin-1-yl)methyl]benzyl}oxy)pyrimidin-4-yl](1,3-benzothiazol-2-yl)acetonitrile,

(3H-Benzothiazol-2-ylidene)-{2-[4-(4-[1,2,4]oxadiazol-3-ylmethyl-piperazin-1-ylmethyl)-benzyloxy]-pyrimidin-4-yl}-acetonitrile,

4-(4-{4-[(3H-Benzothiazol-2-ylidene)-cyano-methyl]-pyrimidin-2-yloxymethyl}-benzyl)-piperazine-1-carboxylic acid methyl ester,

2-[4-(4-{4-[(3H-Benzothiazol-2-ylidene)-cyano-methyl]-pyrimidin-2-yloxymethyl}-benzyl)-piperazin-1-yl]-acetamide,

(2-{4-[4-(2-Amino-acetyl)-piperazin-1-ylmethyl]-benzyloxy}-pyrimidin-4-yl)-(3H-benzothiazol-2-ylidene)-acetonitrile,

[4-(4-{4-[(3H-Benzothiazol-2-ylidene)-cyano-methyl]-pyrimidin-2-yloxymethyl}-benzyl)-piperazin-1-yl]-acetic acid methyl ester,

(3H-Benzothiazol-2-ylidene)-(2-{4-[4-(2-methoxy-ethyl)-piperazin-1-ylmethyl]-benzyloxy}-pyrimidin-4-yl)-acetonitrile,

4-(4-{4-[(3H-Benzothiazol-2-ylidene)-cyano-methyl]-pyrimidin-2-yloxymethyl}-benzyl)-piperazine-1-carboxylic acid dimethylamide,

(3H-Benzothiazol-2-ylidene)-{2-[4-(4-ethyl-piperazin-1-ylmethyl)-benzyloxy]-pyrimidin-4-yl}-acetonitrile, and

(3H-Benzothiazol-2-ylidene)-(2-{4-[4-(2-hydroxy-ethyl)-piperazin-1-ylmethyl]-benzyloxy}-pyrimidin-4-yl)-acetonitrile.

Claims 17 to 19. (Canceled)

Claim 20. (Currently Amended) A pharmaceutical composition, comprising:


a therapeutically effective amount of the piperazine benzothiazole compound according to claim 11 with a pharmaceutically acceptable carrier.

Claim 21. (Previously Presented ) A method of treating ischemia, comprising:


administering a therapeutically effective amount of the pharmaceutical composition according to claim 20 to a subject in need of treatment for ischemia.

Claim 22. (Previously Presented) A process for the preparation of a piperazine benzothiazole compound claimed in claim 11, comprising:

reacting a pyrimidinylbenzothiazole compound of formula (IV)



with a piperazinyl alcohol compound of formula (V)



wherein R, R<sup>1</sup> and n are as defined in claim 11, thereby preparing the piperazine benzothiazole compound of claim 11.